Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and res...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359231171580 |
| _version_ | 1827957093331632128 |
|---|---|
| author | Karen-Lise Garm Spindler Anders Jakobsen |
| author_facet | Karen-Lise Garm Spindler Anders Jakobsen |
| author_sort | Karen-Lise Garm Spindler |
| collection | DOAJ |
| description | Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and results can be transferred to a pan-cancer concept if relevantly investigated. The purpose of this overview is to discuss the current evidence for ctDNA as a marker of response in metastatic CRC (mCRC) and to propose criteria for definitions of response to systemic therapies applicable in prospective clinical trials. We discuss the literature, which supports a new definition of ctDNA Response Evaluation Criteria in Solid Tumors. Finally, we discuss the challenges in preparations of the optimal trial design to establish the true clinical utility of ctDNA. |
| first_indexed | 2024-04-09T15:14:45Z |
| format | Article |
| id | doaj.art-1d7e9a290c5a4061a2ec34857556dae7 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-09T15:14:45Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-1d7e9a290c5a4061a2ec34857556dae72023-04-30T06:04:05ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-04-011510.1177/17588359231171580Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancerKaren-Lise Garm SpindlerAnders JakobsenInterest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and results can be transferred to a pan-cancer concept if relevantly investigated. The purpose of this overview is to discuss the current evidence for ctDNA as a marker of response in metastatic CRC (mCRC) and to propose criteria for definitions of response to systemic therapies applicable in prospective clinical trials. We discuss the literature, which supports a new definition of ctDNA Response Evaluation Criteria in Solid Tumors. Finally, we discuss the challenges in preparations of the optimal trial design to establish the true clinical utility of ctDNA.https://doi.org/10.1177/17588359231171580 |
| spellingShingle | Karen-Lise Garm Spindler Anders Jakobsen Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer Therapeutic Advances in Medical Oncology |
| title | Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer |
| title_full | Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer |
| title_fullStr | Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer |
| title_full_unstemmed | Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer |
| title_short | Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer |
| title_sort | circulating tumor dna response evaluation criteria in solid tumors can we recist focus on colorectal cancer |
| url | https://doi.org/10.1177/17588359231171580 |
| work_keys_str_mv | AT karenlisegarmspindler circulatingtumordnaresponseevaluationcriteriainsolidtumorscanwerecistfocusoncolorectalcancer AT andersjakobsen circulatingtumordnaresponseevaluationcriteriainsolidtumorscanwerecistfocusoncolorectalcancer |